-$0.20 EPS Expected for Minerva Neurosciences, Inc. (NASDAQ:NERV) This Quarter

Wall Street brokerages expect Minerva Neurosciences, Inc. (NASDAQ:NERVGet Rating) to post earnings per share (EPS) of ($0.20) for the current fiscal quarter, according to Zacks. Zero analysts have made estimates for Minerva Neurosciences’ earnings, with the highest EPS estimate coming in at ($0.18) and the lowest estimate coming in at ($0.22). Minerva Neurosciences posted earnings per share of ($0.21) during the same quarter last year, which would indicate a positive year-over-year growth rate of 4.8%. The company is scheduled to announce its next quarterly earnings results on Monday, January 1st.

According to Zacks, analysts expect that Minerva Neurosciences will report full-year earnings of ($0.70) per share for the current financial year, with EPS estimates ranging from ($0.82) to ($0.57). For the next financial year, analysts expect that the company will post earnings of ($0.61) per share, with EPS estimates ranging from ($0.70) to ($0.51). Zacks’ EPS calculations are a mean average based on a survey of analysts that follow Minerva Neurosciences.

Minerva Neurosciences (NASDAQ:NERVGet Rating) last issued its earnings results on Tuesday, March 1st. The biopharmaceutical company reported ($0.12) EPS for the quarter, beating analysts’ consensus estimates of ($0.20) by $0.08.

A number of brokerages recently commented on NERV. StockNews.com started coverage on Minerva Neurosciences in a research report on Monday, April 11th. They issued a “sell” rating for the company. HC Wainwright decreased their price objective on Minerva Neurosciences to $5.00 and set a “buy” rating for the company in a report on Friday, March 4th. Finally, Zacks Investment Research raised Minerva Neurosciences from a “hold” rating to a “buy” rating and set a $0.75 price objective for the company in a report on Saturday, March 5th.

Shares of Minerva Neurosciences stock opened at $0.78 on Friday. Minerva Neurosciences has a one year low of $0.63 and a one year high of $3.54. The firm has a market capitalization of $33.28 million, a price-to-earnings ratio of -0.66 and a beta of 0.93. The business has a 50-day simple moving average of $0.75 and a 200 day simple moving average of $0.99.

Several institutional investors and hedge funds have recently modified their holdings of NERV. GSA Capital Partners LLP increased its position in shares of Minerva Neurosciences by 26.0% during the third quarter. GSA Capital Partners LLP now owns 480,629 shares of the biopharmaceutical company’s stock valued at $836,000 after acquiring an additional 99,141 shares during the last quarter. BlackRock Inc. increased its position in shares of Minerva Neurosciences by 20.2% during the third quarter. BlackRock Inc. now owns 488,370 shares of the biopharmaceutical company’s stock valued at $850,000 after acquiring an additional 81,904 shares during the last quarter. Acadian Asset Management LLC increased its position in shares of Minerva Neurosciences by 3.4% during the fourth quarter. Acadian Asset Management LLC now owns 1,768,685 shares of the biopharmaceutical company’s stock valued at $1,414,000 after acquiring an additional 58,202 shares during the last quarter. Rafferty Asset Management LLC purchased a new stake in shares of Minerva Neurosciences during the third quarter valued at approximately $85,000. Finally, Geode Capital Management LLC increased its position in shares of Minerva Neurosciences by 9.7% during the third quarter. Geode Capital Management LLC now owns 488,813 shares of the biopharmaceutical company’s stock valued at $850,000 after acquiring an additional 43,034 shares during the last quarter. 55.03% of the stock is owned by institutional investors.

Minerva Neurosciences Company Profile (Get Rating)

Minerva Neurosciences, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of product candidates for the treatment of central nervous system diseases. Its lead product candidate is roluperidone for the treatment of schizophrenia; and MIN-301, a soluble recombinant form of the neuregulin-1b1 protein for the treatment of Parkinson's disease and other neurodegenerative disorders.

Further Reading

Get a free copy of the Zacks research report on Minerva Neurosciences (NERV)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Minerva Neurosciences (NASDAQ:NERV)

Receive News & Ratings for Minerva Neurosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Minerva Neurosciences and related companies with MarketBeat.com's FREE daily email newsletter.